Description
Molnuvid (Molnupiravir) 200 mg
Molnuvid 200 mg contains the antiviral medicine molnupiravir. It is an oral capsule product used for the treatment of COVID-19 in selected patients, depending on the regulatory status and local prescribing information available in a given country. Official sources describe molnupiravir as an antiviral that reduces SARS-CoV-2 replication.
Active Ingredient and Medicine Class
Active ingredient: molnupiravir.
Medicine class: antiviral; a ribonucleoside prodrug. After conversion in the body, it interferes with viral RNA replication.
Established Medical Uses
Regulatory sources describe molnupiravir for the treatment of COVID-19 in adults in situations where authorised or approved use applies under local rules. EMA materials identify it as a treatment for COVID-19, and FDA materials describe it as an authorised oral antiviral for certain adults at high risk of progression when other options are not suitable or accessible.
How It Works
Molnupiravir is converted in the body to a form that is incorporated into the virus’s genetic material. This increases errors during viral RNA copying, which reduces the virus’s ability to multiply. Human and regulatory sources describe this as an error-inducing mechanism against SARS-CoV-2.
Important Safety Information
Key safety concerns include pregnancy-related risk. FDA materials state that molnupiravir may cause fetal harm and is not recommended in pregnancy unless the expected benefit outweighs the risk in an individual case. FDA materials also advise caution for people of reproductive potential.
Hypersensitivity reactions, including serious allergic reactions, have been reported. EMA and FDA sources also note the need to consider breastfeeding-related precautions and other reproductive safety issues. Drug-interaction risk is generally considered limited compared with some other antivirals, but official product information should still be checked before use.
Possible Side Effects
Commonly reported adverse effects include diarrhoea, nausea, dizziness, headache, vomiting, rash and urticaria. Serious reactions can include hypersensitivity and allergic reactions. Official sources also highlight embryo-fetal toxicity as a major safety concern.
Scientific Evidence
In the phase 3 MOVe-OUT trial, molnupiravir was studied in nonhospitalised adults with mild-to-moderate COVID-19 and risk factors for severe disease. PubMed-indexed reports from this program describe antiviral activity, reduced viral replication, and clinical benefit signals in selected populations, while later analyses have also explored virologic and symptom outcomes.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, product label, or individual assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA) — Lagevrio (molnupiravir) EPAR ([ema.europa.eu](https://www.ema.europa.eu/en/medicines/human/EPAR/lagevrio?utm_source=openai))
- U.S. Food and Drug Administration (FDA) — Fact Sheet for Healthcare Providers: Emergency Use Authorization for LAGEVRIO (molnupiravir) capsules ([fda.gov](https://www.fda.gov/media/155054/download?os=0&utm_source=openai))
- Jayk Bernal A, et al. “Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.” New England Journal of Medicine (2021). PubMed ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34914868/?utm_source=openai))
